Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWR NASDAQ:FGEN NASDAQ:MRTX NASDAQ:NKTR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$76.67-3.8%$65.94$14.30▼$82.26$11.22B1.281.91 million shs1.75 million shsFGENFibroGen$9.77+8.3%$9.21$4.85▼$12.60$39.57M0.7740,794 shs31,125 shsMRTXMirati Therapeutics$58.70$58.82$27.30▼$64.41$4.12B0.772.76 million shsN/ANKTRNektar Therapeutics$70.62-5.0%$78.32$7.99▼$109.00$2.51B1.241.31 million shs1.27 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals-3.79%+5.47%+8.06%+20.13%+414.22%FGENFibroGen0.00%0.00%0.00%0.00%+30.31%MRTXMirati Therapeutics0.00%0.00%0.00%0.00%0.00%NKTRNektar Therapeutics-4.99%-13.76%-15.14%-1.00%+558.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$76.67-3.8%$65.94$14.30▼$82.26$11.22B1.281.91 million shs1.75 million shsFGENFibroGen$9.77+8.3%$9.21$4.85▼$12.60$39.57M0.7740,794 shs31,125 shsMRTXMirati Therapeutics$58.70$58.82$27.30▼$64.41$4.12B0.772.76 million shsN/ANKTRNektar Therapeutics$70.62-5.0%$78.32$7.99▼$109.00$2.51B1.241.31 million shs1.27 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals-3.79%+5.47%+8.06%+20.13%+414.22%FGENFibroGen0.00%0.00%0.00%0.00%+30.31%MRTXMirati Therapeutics0.00%0.00%0.00%0.00%0.00%NKTRNektar Therapeutics-4.99%-13.76%-15.14%-1.00%+558.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 2.83Moderate Buy$87.8014.52% UpsideFGENFibroGen 2.00Hold$43.00340.12% UpsideMRTXMirati Therapeutics 0.00N/AN/AN/ANKTRNektar Therapeutics 2.73Moderate Buy$149.63111.87% UpsideCurrent Analyst Ratings BreakdownLatest FGEN, ARWR, NKTR, and MRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026ARWRArrowhead Pharmaceuticals Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$35.00 ➝ $46.005/11/2026NKTRNektar Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$95.00 ➝ $80.005/8/2026ARWRArrowhead Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$80.00 ➝ $87.005/8/2026NKTRNektar Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$105.00 ➝ $192.005/6/2026ARWRArrowhead Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)5/1/2026ARWRArrowhead Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$88.004/22/2026NKTRNektar Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/21/2026ARWRArrowhead Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$78.00 ➝ $100.004/21/2026NKTRNektar Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$123.00 ➝ $151.004/21/2026NKTRNektar Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$70.00 ➝ $95.004/20/2026NKTRNektar Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$151.00 ➝ $178.00(Data available from 5/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$622.01M17.36$0.11 per share667.42$4.25 per share18.04FGENFibroGen$29.62M1.34N/AN/A($50.89) per share-0.19MRTXMirati Therapeutics$12.44M331.01N/AN/A$17.31 per share3.39NKTRNektar Therapeutics$55.23M43.21N/AN/A$17.06 per share4.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$1.63M-$2.15N/AN/AN/A-48.38%-55.09%-18.13%N/AFGENFibroGen-$47.58M$53.480.18N/AN/A2,598.55%N/A-26.27%N/AMRTXMirati Therapeutics-$740.87M-$12.22N/AN/AN/A-1,900.65%-82.15%-67.82%N/ANKTRNektar Therapeutics-$164.08M-$8.42N/AN/AN/A-284.18%-85.40%-39.99%N/ALatest FGEN, ARWR, NKTR, and MRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q2 2026ARWRArrowhead Pharmaceuticals-$1.0950-$0.93+$0.1650-$0.93$73.84 million$73.74 million5/7/2026Q1 2026NKTRNektar Therapeutics-$1.5824-$1.82-$0.2377-$1.82$10.69 million$10.86 million3/12/2026Q4 2025NKTRNektar Therapeutics-$2.69-$1.78+$0.91-$1.78$10.44 million$21.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AFGENFibroGenN/AN/AN/AN/AN/AMRTXMirati TherapeuticsN/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals1.416.236.23FGENFibroGenN/A3.713.60MRTXMirati TherapeuticsN/A7.547.40NKTRNektar TherapeuticsN/A10.214.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%FGENFibroGen72.71%MRTXMirati TherapeuticsN/ANKTRNektar Therapeutics75.88%Insider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals3.60%FGENFibroGen3.07%MRTXMirati Therapeutics3.26%NKTRNektar Therapeutics2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400140.86 million135.79 millionOptionableFGENFibroGen5704.05 million3.92 millionOptionableMRTXMirati Therapeutics58770.15 million67.86 millionNo DataNKTRNektar Therapeutics22033.79 million32.94 millionOptionableFGEN, ARWR, NKTR, and MRTX HeadlinesRecent News About These CompaniesPatient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 SharesMay 16 at 1:01 PM | fool.comAssessing Nektar Therapeutics (NKTR) Valuation After Strong REZPEG Prospects And Recent Share Price MomentumMay 14 at 5:51 PM | finance.yahoo.comNektar Therapeutics (NASDAQ:NKTR) Price Target Lowered to $80.00 at WedbushMay 12, 2026 | americanbankingnews.comWedbush Cuts Nektar Therapeutics (NASDAQ:NKTR) Price Target to $80.00May 11, 2026 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Stock Price Expected to Rise, Piper Sandler Analyst SaysMay 10, 2026 | americanbankingnews.comNektar Therapeutics Establishes New Equity Distribution AgreementMay 10, 2026 | theglobeandmail.comNektar Therapeutics (NASDAQ:NKTR) Rating Lowered to "Sell" at Wall Street ZenMay 9, 2026 | marketbeat.comNektar Therapeutics Charts Aggressive Path With REZPEGMay 8, 2026 | tipranks.comNektar Q1 Earnings & Revenues Lag Estimates, Pipeline in FocusMay 8, 2026 | zacks.comNektar Therapeutics (NASDAQ:NKTR) Price Target Raised to $192.00 at Piper SandlerMay 8, 2026 | marketbeat.comNektar Therapeutics Q1 Earnings Call HighlightsMay 8, 2026 | marketbeat.comNektar Therapeutics (NKTR) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comNektar Therapeutics: Strong Cash Position and Late‑Stage Autoimmune Pipeline Underpin Attractive Risk‑Reward and Outperform RatingMay 7, 2026 | tipranks.comNektar Therapeutics Reports First Quarter 2026 Financial ResultsMay 7, 2026 | prnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers - NKTRMay 7, 2026 | prnewswire.comNEKTAR DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - NKTRMay 5, 2026 | newsfilecorp.comNPomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers – NKTRMay 5, 2026 | globenewswire.comDeadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitMay 5, 2026 | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor HarmMay 5, 2026 | globenewswire.comNektar Therapeutics: This Stock Went Up 10x In The Last Year And It's Still CheapMay 5, 2026 | seekingalpha.comNKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026May 5, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFGEN, ARWR, NKTR, and MRTX Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$76.67 -3.02 (-3.79%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$76.56 -0.11 (-0.14%) As of 05/15/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.FibroGen NASDAQ:FGENFibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Mirati Therapeutics NASDAQ:MRTXMirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.Nektar Therapeutics NASDAQ:NKTR$70.62 -3.71 (-4.99%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$70.30 -0.32 (-0.45%) As of 05/15/2026 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware Viking Sails to All-Time Highs—Fundamentals Signal More to Come YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
